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Dear Editor, 
Molluscum contagiosum (MC) is a very common 
skin infection caused by a molluscipox virus gene of 
the poxvirus family. It usually occurs in young chil-
dren, sexually active adults, and immunocompro-
mised individuals. The typical clinical picture of this 
infection is characterized by asymptomatic flesh-col-
ored, single or multiple papules, measuring 2-6 mm 
in diameter with a central umbilication that occur on 
the skin and the mucous membranes. In adults, the 
skin lesions are predominantly located in the geni-
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tal region, whereas in children they are found on the 
trunk, the extremities, and the face. 
MC is generally regarded as a self-limited disease; 
however, its treatment is usually advisable consider-
ing its potentially protracted course and the risk of 
superinfection, scarring, autoinoculation, and trans-
mission to other members of the community. 
A large number of approaches to the treatment 
of MC have been used so far (none of them approved 
by the Food and Drug Administration (FDA)) includ-
No Gender Age (years) Location of the lesions response (%) Duration of 
treatment (weeks)
1 M 8 Face 100 6
2 F 10 Trunk 82.35 10
3 F 12 Face 100 6
4 M 7 Extremities 84.61 10
5 M 5 Trunk 100 7
6 M 8 Extremities 100 5
7 M 8 Trunk 100 4
8 F 11 Face 100 5
9 M 8 Face 61.13 12
10 F 7 Trunk 100 5
11 F 4 Extremities 100 5
12 F 3 Extremities, trunk* 100 3
13 F 7 Trunk 100 5
14 F 12 Face 100 6
15 M 13 Face 100 6
16 M 10 Trunk 100 5
17 M 8 Extremities 100 4
18 F 9 Trunk 100 8
19 M 6 Face 55.55 11
20 M 5 Face 63.63 12
21 F 9 Face 100 5
22 F 12 Extremities 100 6
23 F 11 Trunk 58.33 10
M = male; F = female;  * = disseminated lesions
Table 1. Demographic data and therapeutic response of the children with molluscum 
contagiosum which were  treated  with topical imiquimod under occlusion      
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ing ablative regimens (curettage, electrodessication, 
cryotherapy, laser therapy) and topical or systemic 
pharmacologic agents (tretinoin, cantharidin, trichlo-
roacetic and salicylic acid, potassium hydroxide, in-
terferon-alfa, and cimetidine). 
Imiquimod is a topically applicable Toll-like recep-
tor (TLr)-7/8 agonist, which is capable of stimulating 
the innate cutaneous immunity and the cellular arm 
of the adaptive immune response and of exerting 
potent anti-viral, anti-tumor and immunoregulatory 
effects (1). originally approved for the treatment of 
external genital and perianal warts in adults, imiqui-
mod was later approved for the therapy of basal cell 
carcinomas and actinic keratoses and has also been 
used in the management of several off-label indica-
tions including cutaneous infections and neoplasms. 
our group has successfully used topical imiqui-
mod in the treatment of a variety of dermatoses in-
cluding granuloma annulare, pyogenic granuloma, 
herpes labialis, and lichen striatus (2-6). Moreover, we 
have examined the topical application of imiquimod 
over the last twelve years in the treatment of 23 chil-
dren with MC, the demographic data and the thera-
peutic response of which are summarized in Table 1. 
Seventeen out of 23 children (73.91%) treated with 
topical imiquimod once daily under occlusion (in-
cluding two cases with disseminated lesions) showed 
a complete remission within 3 to 8 weeks of treat-
ment. Furthermore, 6 other children who switched to 
other forms of treatment showed a partial remission 
(55.55%-84.61%) after 10 to 12 weeks of therapy. The 
only cutaneous adverse reaction to topical imiqui-
mod was a mild to moderate irritation in the appli-
cation area that was observed in all treated children, 
whereas no systemic side effects could be seen. our 
findings are compatible with those of other groups, 
who also demonstrated the therapeutic efficacy and 
safety of topical imiquimod in MC.
Interestingly, in two very similar subsequent pa-
pers Katz and Swetman (7) and Katz (8,9) expressed 
the view that “imiquimod is neither efficacious nor 
safe in the treatment of MC in children”. This view was 
not the result of the author’s clinical experience but 
was exclusively based on the findings of two random-
ized clinical trials (rCTs). These were carried out in 
2006 upon request of the FDA from the drug’s origi-
nal manufacturer (3M) and “definitely showed that 
imiquimod does not effectively treat MC in children”. 
Surprisingly, today, 10 years after their completion, 
these rCTs still remain unpublished, whereas the cor-
responding FDA site provides no information with 
regard to the researchers, the centers in which these 
trials were conducted, their research protocol, and 
the demographic data of the enrolled patients. 
In a very recent review on childhood skin infec-
tions, rush and Dinulos (10), exclusively based on 
Dr. Katz’s paper, fully adopted this view and stated 
that “imiquimod is neither efficacious nor safe in the 
treatment of MC”, although they admit that the rCTs 
cited by the latter still remain unpublished. In con-
trast to these authors, we reject Dr Katz’s inexplicable 
request to the medical community to fully ignore 
all articles published in peer-reviewed journals that 
demonstrate the efficacy and safety of imiquimod 
in MC. We do not claim that imiquimod is a panacea. 
however, based on our clinical experience and that of 
other groups, we are convinced that this compound 
represents a very useful and painless tool in the der-
matologic arsenal for the treatment of MC, an other-
wise difficult to manage dermatosis, particularly in 
children.
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